Are Anti- Fibrinolytic Drugs the Magic Bullets for Perioperative Hemostasis?
|
|
- Maximillian Ramsey
- 5 years ago
- Views:
Transcription
1 Are Anti- Fibrinolytic Drugs the Magic Bullets for Perioperative Hemostasis? Daniela Filipescu, MD. PhD. Assoc. Prof. of Anesthesia & Intensive Care Carol Davila University Emergency Institute of Cardiovascular Diseases Department of Cardiac Anesthesia & Intensive Care Bucharest, Romania
2 Disclosure Competing conflicts of interest Grants and speaker fees from Bayer, Novo Nordisk, Pfizer and Sanofi Member of Multicenter Studies of Perioperative Ischemia (McSPI) Research Group
3 Anti-fibrinolytic drugs Serine protease- inhibitors Aprotinin Lysine analogues Tranexamic acid Epsilon aminocaproic acid
4 The ideal hemostatic agent Will clot inappropriate bleeding Will not clot normal vessels Favorable pharmacokinetics Easy to store and use Monitored by a validated laboratory assay Inexpensive No side effects
5 Aprotinin Serine protease inhibitor from bovine pancreas In-vivo inhibition of serine proteases by Aprotinin prevents plasmin-mediated fibrinolysis preserves platelet function and number inhibits contact activation inhibits complement activation anti-inflammatory and anti-oxidant effects McEvoy MD, et al. Anesth Analg 2007;105:
6 Mode of action of lysine analogues Mannucci P, Levi M. NEJM 2007;356:
7 Aprotinin Saga Launched in Germany Royston [Lancet] 22 patients Aprotinin [11] Control [11] FDA Approval Limited indication Expanded indication Aprotinin s anti-inflammatory properties Mangano D [NEJM] [JAMA] Karkouti K [Transfusion] BART [NEJM]
8 RCT Multicenter Blinded High-risk cardiac surgery 2331 patients Fergusson DA, et al. NEJM 2008;358:2319
9 Why do the BART findings differ from those of meta-analyses of previous trials? Previous meta-analyses did not detect an increased risk of death for aprotinin because of: pooling data from many small trials that were not designed to study mortality the high proportion of data from trials with low or moderate quality the inclusion of a mixture of both high-risk and low-risk patients the frequent failure to ascertain the deaths of patients after hospital discharge Ray WA, Stein CM. NEJM 2008;358:2398
10 RCTs vs. observational studies Best evidence on EFFICACYof therapy comes from randomized trials - Caveat: Low quality RCTs may overestimate benefits of therapy Best evidence on HARMof therapy will often come from large, properly analyzed nonrandomized trials - Caveat: Observational study must be of high quality Large sample size Proper adjustment for baseline differences to reduce confounding by indication Transparent Sponsor-Independent Vandenbroucke SA. CMAJ 2006;5:174 Ray & Stein. NEJM 2008;358:2398
11 Life without aprotinin Retrospective analysis 7988 pts Cardiac surgery Aprotinin-free blood saving program Specific hemostasis/coagulation management protocol Ranucci M et al. Acta Scand 2009;53:573
12 What have we learned from the aprotinin saga? 1. Avoid redundancy of efficacy trials in drugs evaluation 2. Necessity of head to head comparisons 3. Safety studies after regulatory approval of a drug are urgently needed 4. Safety concerns have to be taken seriously 5. Use of mortality as an end-point
13 Lysine Aprotinin: analogues: Key Key limitations limitations Multiple dosage regimens Undefined pharmacokinetics Variable plasma levels Absence of direct monitoring of in vivo activity Undefined end-point in determination of the adequacy of therapy Undefined timing of discontinuation of therapy
14 Heterogeneity of dosing Tranexamic acid Pharmacokinetic Fiechtner Anesth Analg 2001 Dose/reponse Horrow Anesth 1995 Casati JTCS 2000 BART NEJM 2008 Target: 20 μg/ml 5.4 mg/kg 5 mg/kg/h 20 mg/l CPB 10 mg/kg 1 mg/kg/h 1000 mg 400 mg/h 500 mg/cpb 30 mg/kg 16 mg/kg/h 2 mg/kg/cpb Renal failure moderate: 2.5 mg/kg/h severe: 1.25 mg/kg/h Renal dysfunction moderate: 200 mg/h severe: 100 mg/h Bolus before induction: 1-10 g or mg/kg CPB: g (2 mg/kg) Infusion: g or g/h ( mg/kg/h)
15 Dose-dependent effects Sukeik M at al. Journal of Bone and Joint Surgery 2011: 39-46
16 Overdosing!!! - TXA 30 mg/kg + 16 mg/kg/h + 2 mg/kg prime 12.5 mg/kg mg/kg/h + 1 mg/kg prime 8 mg/kg + 4 mg/kg/h mg/kg prime Dowd NP et al. Anesthesiology 2002;97:390
17 Overdosing - EACA Dose: Induction 100 mg/kg + 30 mg/kg/h + 5 g prime Plasma concentrations Greilich PE et al. Anesth Analg 2009;109:15
18 Efficacy of anti-fibrinolytic drugs 252 RCTs Over 25,000 participants Type of surgery Cardiac 173 Orthopedic 53 Liver 14 Vascular 5 Thoracic 4 Henry DA, et al. Cochrane Database of Systematic Reviews 2011
19 Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion All types of surgery Compared to control TXA significantly reduced the need for allogeneic blood transfusion by a relative 39% Cardiac surgery 32%, orthopedic surgery 51%, liver surgery no reduced risk Compared to control EACA significantly reduced the need for allogeneic blood transfusion by a relative 19% Henry DA, et al. Cochrane Database of Systematic Reviews 2011
20 Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion Data from the head-to-head trials suggest an advantage of aprotinin over the lysine analogues TXA and EACA in terms of reducing perioperative blood loss, but the differences were small However, any small advantage needs to be moderated by possible publication bias and uncertainty over the Aprotinin appeared more effective in reducing the comparative need for RBC dose-response transfusion (10%) relationship. Aprotinin reduced the need for re-operation due to bleeding by 54%. A similar trend was seen with EACA but not TXA Henry DA, et al. Cochrane Database of Systematic Reviews 2011
21 More heparin needed on CPB?! 45% 45% 30% 19% 15% 0% Aprotinin TXA Dietrich W, et al. Anesth Analg 2008;107: Andreasen JJ, Nielsen C. Eur J Cardiohorac Surg 2004;311 Maddali MM, et al. Asian Cardiovasc Thorac Ann 2007;313
22
23
24 Antifibrinolytics in patients on aspirin 24-hour chest-tube drainage McIlroy D R et al. Br. J. Anaesth. 2009;102:
25 Antifibrinolytics in patients on aspirin Proportion of patients receiving blood products McIlroy D R et al. Br. J. Anaesth. 2009;102:
26 Antifibrinolytics in patients on aspirin Re-exploration McIlroy D R et al. Br. J. Anaesth. 2009;102:
27 ATACAS Aspirin and Tranexamic Acid for Coronary Artery Surgery A collaborative randomized controlled trial being conducted by the ANZCA Trials Group and the Australian NHMRC Centre of Clinical Research Excellence in Therapeutics Myles PS, et al. Am Heart J 2008:224
28 Eur J Anesthesiol 2011:57-62 aspirin & clopidogrel aspirin & clopidogrel
29 Safety of lysine analogues Mortality Thromboembolic complications Adverse effects
30 Effect on thrombus formation M.Sperzel and J. Huetter. J Thromb Haemost 2007;5:2113-8
31 Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion Adverse outcome The lysine analogues appear to be free of serious adverse effects (myocardial infarction, renal dysfunction, stroke, deep venous thrombosis). When aprotinin was compared directly with either, or both, of the two lysine analogues it resulted in a significant increase in the risk of death (RR 1.39, 95% CI 1.02, 1.89). Henry DA, et al. Cochrane Database of Systematic Reviews 2011
32 Meta-analysis comparing mortality between aprotinin and TXA or EACA Ferraris VA, et al. Ann Thorac Surg 2011;91:
33 Retrospective single-center cohort study Study period: pts. (1017 aprotinin, TXA) Aprotinin tends to have a better risk benefit profile than tranexamic acid in high-risk, but not low- to moderate-risk patients Aprotinin use in high-risk cases may be therefore warranted Karkouti K, et al. Anesth Analg 2010;110:21
34 Aprotinin TXA Karkouti K, et al. Anesth Analg 2010;110:21
35 Vascular and death event in hip fracture 110 pts. operated in less than 48 hours after injury TXA 15 mg/kg x 2 6 weeks follow up No symptomatic venous thrombosis or pulmonary embolism A non-significant but three fold increased risk of vascular events with the use of TXA when compared with placebo 1 asymptomatic proximal DVT, 4 asymptomatic distal DVTs, 3 acute coronary syndromes, 1 stroke, 1 death.
36 Adverse outcome All patients Aprotinin N=557 Tranexamic acid N=336 Renal failure * Late ischemic stroke 3.4* 0.9 Late neurologic disability Convulsive seizures Hospital stay Mortality Sander M, et al. Critical Care 2010;14:R148
37 Adverse outcome Open heart Aprotinin N=215 Tranexamic acid N=105 Renal failure * Myocardial infarction 0 1.9* Late ischemic stroke Late neurologic disability 7 1 Convulsive seizures * Hospital stay Mortality * Sander M, et al. Critical Care 2010;14:R148
38 Incidence: 3.8% vs. 1.3%
39 Seizures -mechanisms Blockade of GABA-mediated inhibition in the CNS Experimental epileptogenic effect when applied topically to the cortex, intrathecally and iv. Iplikcioglu AC, et al. Surg Neurol 2003;59:10 Furtmuller R, et al. J Pharmacol ExpTer 2002;301: De Leede-van der Maarl MG, et al. J Neurol 1999: 843
40 Incidence of seizures Dose-dependency 16 Without TXA ,4 Children Adult 4 g 10 Dose 67 mg/kg ,4 3,5 4,6 4,8 Dose 109 mg/kg 0 SEIZURES (%) Martin K, et al. Anesth Analg 2008:1783 Breuer T, et al. Eur J Cardiothorac Surg 2009:167 Jerath A, et al. Can J Anesth 2009;56:abstract S7
41 Tranexamic or EACA acid? 604 open heart surgery patients Equipotent doses Higher blood loss with EACA Trends of increased re-operation rate No difference in transfusion Higher incidence of new onset seizures in the TXA group 7.6 % vs.3.3 % Increased rate of renal dysfunction in the EACA group 30 % vs.20 %
42
43 Temporally and regionally heterogeneity in plasmin activity - EACA Reust DL et al. Ann Thorac Sug 2010;89:1538
44 Stand back and look at the Big Picture!
45 TXA & EACA are efficacious, however There are not enough safety data on the use of TXA and EACA Potential harms of inhibiting endogenous fibrinolytic system have not been systematically reviewed
46
47 Antifibrinolytics in trauma CRASH-2 trial (Lancet 2010: 376:23-32) RCT of 20,211 adult trauma patients in 274 hospitals in 40 countries Inclusion criteria: clinically significant hemorrhage Randomized to receive placebo or TXA 1 g over 10 min then infusion 1 g over 8h Treatment initiated within 8 hours of injury Staff blinded to treatment arm Results: Blood transfusion rate not different (50.4% vs 51.3%)
48 n=
49 Figure Tissue injury and fibrinolysis Jerrold H Levy. The Lancet 2010;376:3-4
50 TXA for every patient? Do not extrapolate
51 Which patients could benefit from antifibrinolytics? PAI- 1 is a natural antifibrinolytic 5G carriers showed greater tendency to post-cpb chest tube blood loss. 5G homozygotes, not receiving TXA, showed significantly more postoperative bleeding than patients with other PAI-1 genotypes. 5G homozygotes who received TXA showed the greatest blood-sparing benefit. Iribarren JL, et al. Anesthesiology 2008;108: Duggan E, et al. Anesth Analg 2007;104:
52
53 Factors influencing clinical phenotype in the perioperative period Jochen D. Muehlschlegel and Simon C. Body Am. J. Hematol. 2008; 83:
54 Nadia Comaneci 1976: First Perfect Score of 10 In Olympics Hemostasis is like a balance beam performance Both efficacy and safety of drugs affecting hemostasis are important, and if you fail to balance efficacy and safety, the patient may get hurt
55 We must move forward and focus our attention on ways to limit blood loss and transfusion that are safe and effective for patients undergoing surgery Revision of protocols may be more important than the choice of a pro-hemostatic drug Drugs might one day be tailormade for individuals and adapted to each person s own genetic makeup
56
57 Units of RBC
58 24 h bloodloss (ml) n=269
59 Markers of fibrinolysis taken from the circuit and the wound during cardiac surgery Chung JH, et al. Circulation 1996;93:2014 Tabuchi N, et al. J Thorac Cardiovasc Surg 1993;106:828 Edmunds LH. Ann Thorac Surg 2010;89:324
60 Timing Thrombosis Research, Vol 73, No6, pp , 1994
61
62 Figure 1 Mortality due to bleeding by subgroups The CRASH-2 collaborators The Lancet 2011;377:
63
64 Overdosing - EACA Plasma concentrations 100 mg/kg + 30 mg/kg + 5 g prime Greilich PE et al. Anesth Analg 2009;109:15 Yurka HG, et al. AnesthAnalg 2011;111:180
Large trials vs observational studies in assessing benefit and harm: the example of aprotinin
Large trials vs observational studies in assessing benefit and harm: the example of aprotinin Dean A. Fergusson, MHA, PhD Senior Scientist and Associate Director, Clinical Epidemiology Program, Ottawa
More informationTransfusion & Mortality. Philippe Van der Linden MD, PhD
Transfusion & Mortality Philippe Van der Linden MD, PhD Conflict of Interest Disclosure In the past 5 years, I have received honoraria or travel support for consulting or lecturing from the following companies:
More informationComparison of Tranexamic Acid and Aminocaproic Acid in Coronary Bypass Surgery
Butler Journal of Undergraduate Research Volume 2 Article 24 2016 Comparison of Tranexamic Acid and Aminocaproic Acid in Coronary Bypass Surgery Lisa K. LeCleir Butler University, lisa.lecleir@gmail.com
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationBias-adjusted adjusted meta-analysis analysis of randomized and
Association of increased mortality with aprotinin administration in cardiac surgery? Bias-adjusted adjusted meta-analysis analysis of randomized and observational studies Society for Clinical Trials, 2011
More informationThe Role of Tranexamic Acid in Patient Blood Management Undergoing Cardiac Surgery
The Role of Tranexamic Acid in Patient Blood Management Undergoing Cardiac Surgery Dr Sarah Armarego FANZCA FANZCP Senior Staff Specialist John Hunter Hospital Newcastle Declaration Former member of a
More informationPublic Assessment Report Scientific discussion. Trasylol (aprotinin) SE/H/1671/01/MR
Public Assessment Report Scientific discussion Trasylol (aprotinin) SE/H/1671/01/MR This module reflects the scientific discussion for the approval of Trasylol. The procedure was finalised on 2018-02-06.
More informationWhen Should I Use Tranexamic Acid for Children? Dr Andrea Kelleher Consultant Adult and Paediatric Cardiac Anaesthetist
When Should I Use Tranexamic Acid for Children? Dr Andrea Kelleher Consultant Adult and Paediatric Cardiac Anaesthetist When? When a drug is licenced for (the proposed) use When its use is supported by
More informationNew data for preventing postoperative hemorrhage with the use of aprotinin
New data for preventing postoperative hemorrhage with the use of aprotinin Nikolaos BAIKOUSSIS MD, MSc, PhD Cardiac Surgeon Ippokrateio General Hospital of Athens No conflict of interest Bleeding
More informationIntraoperative haemorrhage and haemostasis. Dr. med. Christian Quadri Capoclinica Anestesia, ORL
Intraoperative haemorrhage and haemostasis Dr. med. Christian Quadri Capoclinica Anestesia, ORL Haemostasis is like love. Everybody talks about it, nobody understands it. JH Levy 2000 Intraoperative Haemorrhage
More informationThe current place of tranexamic acid in the management of bleeding
Anaesthesia 2015, 70 (Suppl. 1), 50 53 Review Article doi:10.1111/anae.12910 The current place of tranexamic acid in the management of B. J. Hunt 1,2 1 Professor of Thrombosis & Haemostasis, Kings College
More informationAspirin as Venous Thromboprophylaxis
Canadian Society of Internal Medicine Nov 2, 2017 Aspirin as Venous Thromboprophylaxis Bill Geerts, MD, FRCPC Thromboembolism Consultant, Sunnybrook HSC Professor of Medicine, University of Toronto Disclosures
More informationBeta Blockers for ENT Surgery
Beta Blockers for ENT Surgery Dr. Giuliano Michelagnoli U.O. Anestesia e Rianimazione Nuovo Ospedale di Prato Perioperative Beta-Blockade 1. Reduction of perioperative cardiovascular risk 2. Multimodal
More informationHemostatic agents. Jerrold H. Levy APROTININ
Blackwell Science, LtdOxford, UKTRFTransfusion0041-11322004 American Association of Blood BanksDecember 200444Supplement58S62SOriginal ArticleHEMOSTATIC AGENTSLEVY Hemostatic agents Jerrold H. Levy Hemostasis
More informationAntifibrinolytic drugs for acute traumatic injury(review)
Cochrane Database of Systematic Reviews Antifibrinolytic drugs for acute traumatic injury(review) KerK,RobertsI,ShakurH,CoatsTJ KerK,RobertsI,ShakurH,CoatsTJ. Antifibrinolytic drugs for acute traumatic
More informationHow can ROTEM testing help you in cardiac surgery?
How can ROTEM testing help you in cardiac surgery? Complicated bleeding situations can appear intra and post operatively. They can be life-threatening and always require immediate action. A fast differential
More informationUniversity of Pennsylvania Health System Aprotinin Task Force
Aprotinin Use in Adult Cardiac Surgery: A Recommendation Statement from the University of Pennsylvania Health System Center for Evidence-based Practice *Note: This guideline was originally released on
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationOriginal Article Post-Operative Bleeding Pak Armed Forces Med J 2014; 1(1): S13-18
Original Article Post-Operative Bleeding Pak Armed Forces Med J 2014; 1(1): S13-18 COMPARISON OF DIFFERENT DOSES OF TRANEXAMIC ACID ON POST-OPERATIVE BLEEDING IN PATIENTS OF CABG SURGERY Fakher-e-Fayaz,
More informationAdvances in Transfusion and Blood Conservation
Advances in Transfusion and Blood Conservation Arman Kilic, MD Division of Cardiac Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, MD No relevant financial relationships to disclose.
More informationBleeding, Coagulopathy, and Thrombosis in the Injured Patient
Bleeding, Coagulopathy, and Thrombosis in the Injured Patient June 7, 2008 Kristan Staudenmayer, MD Trauma Fellow UCSF/SFGH Trauma deaths Sauaia A, et al. J Trauma. Feb 1995;38(2):185 Coagulopathy is Multi-factorial
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationPre-hospital Administration of Blood Products (PHBP) and Tranexamic acid (TXA): Is the Jury Still Out?
Pre-hospital Administration of Blood Products (PHBP) and Tranexamic acid (TXA): Is the Jury Still Out? Jessica K. Reynolds, MD Assistant Professor of Surgery University of Kentucky, Department of Trauma
More informationBleeding and Management of Coagulopathy
Bleeding and Management of Coagulopathy Jerrold H. Levy, MD, FAHA Professor of Anesthesiology Deputy Chair for Research Emory University School of Medicine Director, Cardiothoracic Anesthesiology CT Anesthesiology
More informationPatient Blood Management Are you providing this? Jeannie Callum, BA, MD, FRCPC Associate Professor, University of Toronto
Patient Blood Management Are you providing this? Jeannie Callum, BA, MD, FRCPC Associate Professor, University of Toronto Disclosures Relevant relationships with commercial entities: Octapharma, CSL Behring
More informationOPCAB IS NOT BETTER THAN CONVENTIONAL CABG
OPCAB IS NOT BETTER THAN CONVENTIONAL CABG Harold L. Lazar, M.D. Harold L. Lazar, M.D. Professor of Cardiothoracic Surgery Boston Medical Center and the Boston University School of Medicine Boston, MA
More informationTXA. Things Change. Tranexamic Acid TXA. Resuscitation 2017 TXA In The ED March 31, MAST Trousers. High Flow IV Fluids.
Resuscitation 2017 In The ED March 31, 2017 Corey M. Slovis, M.D. Vanderbilt University Medical Center Metro Nashville Fire Department Nashville International Airport Nashville, TN SECURE THE ABC S MAST
More informationCADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm
CADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm P. Timothy Pollak, MD, PhD University of Calgary Rocky Mountain/ACP Internal Medicine Meeting,
More informationAprotinin Use in Cardiac Surgery Patients at Low Risk for Requiring Blood Transfusion
Aprotinin Use in Cardiac Surgery Patients at Low Risk for Requiring Blood Transfusion Judith L. Kristeller, Pharm.D., Russell F. Stahl, M.D., FACS, Brian P. Roslund, Pharm.D., and Marie Roke-Thomas, Ph.D.
More informationRecombinant Activated Factor VII: Useful. Department of Surgery Grand Rounds 11/8/10 David Mauchley MD
Recombinant Activated Factor VII: Useful Department of Surgery Grand Rounds 11/8/10 David Mauchley MD Hemostasis and Coagulation Traditional cascade model Two convergent pathways Series of proteolytic
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More information2 Liters. Goal: Basic Algorithm Volume Resuscitation in Trauma. Initial Fluids. Blood. Where do Blood Products Come From?
Goal: Basic Algorithm Volume Resuscitation in Trauma Sanjay Arora MD Associate Professor of Emergency Medicine Keck School of Medicine at USC Los Angeles County + USC Medical Center May 23, 2012 Initial
More informationCurrent status of antifibrinolytics in cardiopulmonary bypass and elective deep hypothermic circulatory arrest
Anesthesiology Clin N Am 21 (2003) 527 551 Current status of antifibrinolytics in cardiopulmonary bypass and elective deep hypothermic circulatory arrest Jeffrey A. Green, MD*, Bruce D. Spiess, MD Department
More informationCABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin
CABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin DISCLOSURES None Objective(s): Our department routinely used
More informationDuration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016
Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be
More informationContents. Version 1.0: 01/02/2010 Protocol# ISRCTN Page 1 of 7
Contents 1. INTRODUCTION... 2 2. STUDY SYNOPSIS... 2 3. STUDY OBJECTIVES... 2 3.1. Primary Objective... 2 3.2. Secondary Objectives... 2 3.3. Assessment of Objectives... 3 3.4. Change the Primary Objective
More information5/30/2013. I have no conflicts of interest to disclose. Alicia Privette, MD Trauma & Critical Care Fellow. Trauma = #1 cause of death persons <40 yo 1
I have no conflicts of interest to disclose. Alicia Privette, MD Trauma & Critical Care Fellow Trauma = #1 cause of death persons
More informationAspirin and Tranexamic Acid for Coronary Artery Surgery Trial. Protocol Number: Anaesthesia Research
Aspirin and Tranexamic Acid for Coronary Artery Surgery Trial Protocol Number: Anaesthesia Research 024 www.atacas.org.au A collaborative project conducted by the Australian and New Zealand College of
More informationVenous Thromboembolism Prophylaxis: Checked!
Venous Thromboembolism Prophylaxis: Checked! William Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Safer
More informationModern Transfusion Management in Cardiovascular Surgery
Modern Transfusion Management in Cardiovascular Surgery Linda Shore-Lesserson, M.D. Professor of Anesthesiology Albert Einstein School of Medicine Montefiore Medical Center Bronx, New York Patient Blood
More informationBlood Management 2016
Blood Management 2016 2016 AAHKS Annual Meeting Orthopaedic Team Member Course Harpal S. Khanuja, MD Associate Professor Chief of Adult Reconstruction Johns Hopkins University Chair, Johns Hopkins Bayview
More informationPRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES
PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES Mario Mandalà, MD Unit of Clinical Research Department of Oncology and Haematology Papa Giovanni XXIII Hospital Cancer Center
More information03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE
CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE Elizabeth L. Detschelt, M.D. Allegheny Health Network Vascular and Endovascular Symposium April 2, 2016 DISCLOSURES I have no
More informationAbstract. Introduction
Brazilian Journal of Medical and Biological Research (2006) 39: 63-69 Tranexamic acid and bleeding after cardiopulmonary bypass ISSN 0100-879X 63 A randomized, double-blind, and placebo-controlled study
More informationMayor lung resection in the presence of anti-platelet therapy. Hans-Beat Ris Service de Chirurgie Thoracique CHUV, Lausanne
Mayor lung resection in the presence of anti-platelet therapy Hans-Beat Ris Service de Chirurgie Thoracique CHUV, Lausanne THORACIC SURGERY IN THE PRESENCE OF ANTI-PLATELET THERAPY Charybdis: Thrombosis
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC 1 st workshop: update to VTE guidelines in 2016 2 nd workshop: VTE controversies + new horizons André Roussin MD, FRCP, CSPQ CHUM
More informationSTEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology
STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post
More informationAnesthesia for Total Hip and Knee Arthroplasty
Anesthesia for Total Hip and Knee Arthroplasty Typical approach Describe anesthesia technique Rather Describe issues with THA and TKA How anesthesia can modify Issues Total Hip Total Knee Blood Loss ++
More informationAlex T. Lee, Christopher R. Barnes, Shweta Jain, and Ronald Pauldine
Case Reports in Anesthesiology Volume 2016, Article ID 1630385, 4 pages http://dx.doi.org/10.1155/2016/1630385 Case Report High Dose, Prolonged Epsilon Aminocaproic Acid Infusion, and Recombinant Factor
More informationMenopausal Hormone Therapy & Haemostasis
Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationSESSION 5 2:20 3:35 pm
SESSION 2:2 3:3 pm Strategies to Reduce Cardiac Risk for Noncardiac Surgery SPEAKER Lee A. Fleisher, MD Presenter Disclosure Information The following relationships exist related to this presentation:
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More informationInstitute of Medical Epidemiology, Biostatistics, and Informatics, University of Halle-Wittenberg, Halle (Saale) 2
Do Randomized and Non-Randomized Trials Yield Different Answers in Similar Populations? Evidence from a 'Meta-Propensity Score' Analysis in Cardiac Surgery Kuss O 1, Legler T 1, Börgermann J 2 1 Institute
More informationENHANCED RECOVERY PROTOCOLS FOR KNEE REPLACEMENT
ENHANCED RECOVERY PROTOCOLS FOR KNEE REPLACEMENT Jeff Gadsden, MD, FRCPC, FANZCA Associate Professor Duke University Department of Anesthesiology Regional Anesthesia and Acute Pain Medicine DISCLOSURES
More informationVTE in the Trauma Population
VTE in the Trauma Population Erik Peltz, D.O. February 11 th, 2015 * contributions from Eduardo Gonzalez, M.D. University of Colorado T-32 Research Fellow The problem. VTE - Scope of the Problem One of
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Medsamic 100 mg/ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains: tranexamic acid 100 mg. For the
More informationInferior Venacaval Filters Valuable vs. Dangerous Valuable Annie Kulungowski. Department of Surgery Grand Rounds March 24, 2008
Inferior Venacaval Filters Valuable vs. Dangerous Valuable Annie Kulungowski Department of Surgery Grand Rounds March 24, 2008 History of Vena Cava Filters Virchow-1846-Proposes PE originate from veins
More information5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016
Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss
More informationBayer Launches Phase III Clinical Study of Trasylol in Elective Spinal Fusion Surgery
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Launches Phase III Clinical Study of Trasylol in Elective Spinal Fusion Surgery Study Examines Effects of
More informationBath, Philip M.W. and England, Timothy J. (2009) Thighlength compression stockings and DVT after stroke. Lancet. ISSN (In Press)
Bath, Philip M.W. and England, Timothy J. (2009) Thighlength compression stockings and DVT after stroke. Lancet. ISSN 0140-6736 (In Press) Access from the University of Nottingham repository: http://eprints.nottingham.ac.uk/1087/1/lancet_clots_1_20090522_4.pdf
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationClinical Controversies in Perioperative Medicine!
Clinical Controversies in Perioperative Medicine! Hugo Quinny Cheng, MD! Division of Hospital Medicine! University of California, San Francisco! Disclosures! Perioperative beta-blockade & statin therapy
More informationRivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional
More informationTop Ten Reasons For Failure To Prevent Postoperative Thrombosis
Top Ten Reasons For Failure To Prevent Postoperative Thrombosis Joseph A. Caprini, MD, MS, FACS, RVT, FACCWS Louis W. Biegler Chair of Surgery NorthShore University HealthSystem, Evanston, IL Clinical
More informationRESPECT Safety Findings
CO-1 SCAI Town Hall Meeting Monday, October 31, 2016 Washington, DC RESPECT Safety Findings John D. Carroll, M.D., MSCAI Professor of Medicine Cardiology University of Colorado School of Medicine University
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationEpidemiology of Venous Thromboembolism in the East. Heng Joo NG Department of Haematology Singapore General Hospital Singapore
Epidemiology of Venous Thromboembolism in the East Heng Joo NG Department of Haematology Singapore General Hospital Singapore Early Literature Tinckler LF Br Med J 1964;1:502 Propagating a notion.. Hwang
More informationAntifibrinolytic drugs, such as the bovine-derived
CMAJ DOI:10.1503/cmaj.081109 The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis David Henry MBChB, Paul Carless BHSc MMedSc (ClinEpid), Dean Fergusson
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More informationTransfusion and Blood Conservation
Transfusion and Blood Conservation Kenneth G. Shann, CCP Assistant Director, Perfusion Services Senior Advisor, Performance Improvement Department of Cardiovascular and Thoracic Surgery Montefiore Medical
More informationVanderbiltEM.com. Prehospital STEMIs. EMS Today 2018 Research That Should Be On Your Radar Screen 3/1/2018
EMS Today 2018 Research That Should Be On Your Radar Screen Corey M. Slovis, M.D. Vanderbilt University Medical Center Metro Nashville Fire Department Nashville International Airport Nashville, TN VanderbiltEM.com
More informationScience Evidence Cost
Anemia, Evidence, and Anemic Evidence: Is there a rational approach to perioperative transfusion? Elizabeth L Whitlock, MD, MSc Resident physician, Anesthesia & Perioperative Care University of California,
More informationShow Me the Evidence: Epidurals, PVBs, TAP Blocks Christopher L. Wu, MD Professor of Anesthesiology The Johns Hopkins Hospital
Show Me the Evidence: Epidurals, PVBs, TAP Blocks Christopher L. Wu, MD Professor of Anesthesiology The Johns Hopkins Hospital Overview Review overall (ERAS and non-eras) data for EA, PVB, TAP Examine
More informationAcute Kidney Injury after Cardiac Surgery: Incidence, Risk Factors and Prevention
Acute Kidney Injury after Cardiac Surgery: Incidence, Risk Factors and Prevention Hong Liu, MD Professor of Clinical Anesthesiology Department of Anesthesiology and Pain Medicine University of California
More informationAntithrombotic therapy in patients with transient ischemic attack / stroke (acute phase <48h)
Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationLow Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders
SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is
More informationC. Michael Gibson, M.S., M.D. Professor of Medicine Harvard Medical School
Novel Strategies to Prevent Pulmonary Embolism and DVT: APEX Trial and Substudies C. Michael Gibson, M.S., M.D. Professor of Medicine Harvard Medical School Conflict of Interest Statement 2 Present Research/Grant
More informationClinical Controversies in Perioperative Medicine
Update on Perioperative Medicine Clinical Controversies in Perioperative Medicine Hugo Quinny Cheng, MD Division of Hospital Medicine University of California, San Francisco Cardiac Medications & Perioperative
More informationBlood transfusions in ICU: double-edged sword. Paul Hébert, MD MHSc(Epid) Physician-in-Chief, CHUM Professor, University of Montreal
Blood transfusions in ICU: double-edged sword Paul Hébert, MD MHSc(Epid) Physician-in-Chief, CHUM Professor, University of Montreal Canadian Critical Care Trials Group Collaborating for Impact Leading
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationHemodynamic Disorders, Thrombosis, and Shock. Richard A. McPherson, M.D.
Hemodynamic Disorders, Thrombosis, and Shock Richard A. McPherson, M.D. Edema The accumulation of abnormal amounts of fluid in intercellular spaces of body cavities. Inflammation and release of mediators
More informationInstitute of Medical Epidemiology, Biostatistics, and Informatics, University of Halle-Wittenberg, Halle (Saale) 2
Do Randomized and Non-Randomized Trials Yield Different Answers in Similar Populations? Evidence from a 'Meta-Propensity Score' Analysis in Cardiac Surgery Kuss O 1, Legler T 1, Börgermann J 2 1 Institute
More informationTRANSFUSION SUPPORT IN HEPATOBILIARY AND PANCREATIC SURGERIES
TRANSFUSION SUPPORT IN HEPATOBILIARY AND PANCREATIC SURGERIES Dr.K.C.Usha Professor & Head Dept: Of Transfusion Medicine & Director, Model Blood Bank Government Medical College Trivandrum,Kerala INTRODUCTION
More informationReplacement of aprotinin by 1-aminocaproic acid in infants undergoing cardiac surgery: consequences for blood loss and outcome
British Journal of Anaesthesia 110 (4): 615 21 (2013) Advance Access publication 4 December 2012. doi:10.1093/bja/aes430 Replacement of aprotinin by 1-aminocaproic acid in infants undergoing cardiac surgery:
More informationTitle: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
More informationDuration of Therapy for Venous Thromboembolism
Duration of Therapy for Venous Thromboembolism Michael B Streiff, MD FACP Associate Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee
More informationOral Anticoagulant Drugs
Oral Anticoagulant Drugs Spoiled sweet clover caused hemorrhage in cattle(1930s). Substance identified as bishydroxycoumarin. Initially used as rodenticides, still very effective, more than strychnine.
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationDepartment of Anesthesiology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China; 2
Int J Clin Exp Pathol 2015;8(7):7978-7987 www.ijcep.com /ISSN:1936-2625/IJCEP0009039 Original Article Epsilon aminocaproic acid reduces blood transfusion and improves the coagulation test after pediatric
More informationBayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the
More informationCurrent evidence in acute pain management. Jeremy Cashman
Current evidence in acute pain management Jeremy Cashman Optimal analgesia Best possible pain relief Lowest incidence of side effects Optimal analgesia Best possible pain relief Lowest incidence of side
More informationGuidelines PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42. Prominent Dutch Cardiovascular Researcher Fired for Scientific Misconduct
PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42 Preoperative, Intraoperative, and Postoperative Factors Associated with Perioperative Cardiac Complications in Patients Undergoing Major Noncardiac
More informationBayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationDeep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H
Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H Authors' objectives To systematically review the incidence of deep vein
More informationBECLOT 500MG. INJECTION Composition : Each ml. contains : Tranexamic Acid I.P. 100mg.
BECLOT 500MG. INJECTION Composition : Each ml. contains : Tranexamic Acid I.P. 100mg. DESCRIPTION Tranexamic acid is a synthetic analog of the amino acid lysine. It is used to treat or prevent excessive
More informationObjectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
More information